Yves Chalandon

11.3k total citations
192 papers, 4.3k citations indexed

About

Yves Chalandon is a scholar working on Hematology, Public Health, Environmental and Occupational Health and Epidemiology. According to data from OpenAlex, Yves Chalandon has authored 192 papers receiving a total of 4.3k indexed citations (citations by other indexed papers that have themselves been cited), including 120 papers in Hematology, 46 papers in Public Health, Environmental and Occupational Health and 43 papers in Epidemiology. Recurrent topics in Yves Chalandon's work include Hematopoietic Stem Cell Transplantation (72 papers), Acute Lymphoblastic Leukemia research (44 papers) and Acute Myeloid Leukemia Research (32 papers). Yves Chalandon is often cited by papers focused on Hematopoietic Stem Cell Transplantation (72 papers), Acute Lymphoblastic Leukemia research (44 papers) and Acute Myeloid Leukemia Research (32 papers). Yves Chalandon collaborates with scholars based in Switzerland, France and United States. Yves Chalandon's co-authors include Eddy Roosnek, Jakob Passweg, Claudine Helg, Norbert Ifrah, Hervé Dombret, Stavroula Masouridi‐Levrat, Xavier Thomas, Véronique Lhéritier, B Chapuis and Françoise Huguet and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Journal of Clinical Oncology.

In The Last Decade

Yves Chalandon

179 papers receiving 4.3k citations

Peers

Countries citing papers authored by Yves Chalandon

Since Specialization

Citations

This map shows the geographic impact of Yves Chalandon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yves Chalandon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yves Chalandon more than expected).

Fields of papers citing papers by Yves Chalandon

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yves Chalandon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yves Chalandon. The network helps show where Yves Chalandon may publish in the future.

Co-authorship network of co-authors of Yves Chalandon

This figure shows the co-authorship network connecting the top 25 collaborators of Yves Chalandon. A scholar is included among the top collaborators of Yves Chalandon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yves Chalandon. Yves Chalandon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Remission of relapsed/refractory classical Hodgkin lymphoma induced by brentuximab vedotin and pembrolizumab combination after allogeneic hematopoietic stem cell transplantation: a case report 2024 ·Frontiers in Immunology ·Federica Giannotti, (unknown), Federico Simonetta, (unknown), (unknown), Stavroula Masouridi‐Levrat, Yves Chalandon, Anne‐Claire Mamez	2
2	Anti-BCMA and GPRC5D bispecific antibodies in relapsed/refractory primary plasma cell leukemia: a case report 2024 ·Frontiers in Immunology ·(unknown), (unknown), Thai Hoa Tran, (unknown), (unknown), (unknown), Federico Simonetta, Anne Cairoli, Holger W. Auner, Kaveh Samii, Yves Chalandon, (unknown)	1
3	Management of adult patients with CMML undergoing allo-HCT: recommendations from the EBMT PH&G Committee 2024 ·Blood ·Francesco Onida, Nico Gagelmann, Yves Chalandon, Guido Kobbe, Marie Robin, Argiris Symeonidis, Théo de Witte, Raphaël Itzykson, Madlen Jentzsch, Uwe Platzbecker, Valeria Santini, Guillermo Sanz, Christof Scheid, Éric Solary, Peter Valent, (unknown), Isabel Sánchez‐Ortega, Ibrahim Yakoub‐Agha, Lisa Pleyer	8
4	Identifying the drivers of overall rating of cancer care: Insights from the second wave of the Swiss Cancer Patient Experiences study 2024 ·Cancer ·(unknown), Manuela Eicher, Isabelle Peytremann‐Bridevaux, Stefan Aebi, Sandro Anchisi, Adrienne Bettini, Yves Chalandon, Pierre‐Yves Dietrich, Michel A. Duchosal, (unknown), Solange Peters, Roger von Moos, Andreas Wicki, Chantal Arditi	1
5	Hepatitis E Virus Infection Epidemiology in Recipients of Allogeneic Hematopoietic Cell Transplant 2023 ·Open Forum Infectious Diseases ·Johan Courjon, (unknown), Sabine Yerly, Pauline Vetter, Manuel Schibler, (unknown), (unknown), Federica Giannotti, Anne‐Claire Mamez, Christian van Delden, Laurent Kaiser, Yves Chalandon, Stavroula Masouridi‐Levrat, Dionysios Neofytos	1
6	SARS-CoV-2 m-RNA Vaccine Response in Immunocompromised Patients: A Monocentric Study Comparing Cancer, People Living with HIV, Hematopoietic Stem Cell Transplant Patients and Lung Transplant Recipients 2023 ·Vaccines ·Natacha Bordry, Anne‐Claire Mamez, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Sabine Yerly, (unknown), (unknown), Mariagrazia Di Marco, Nicolas Mach, Paola M. Soccal, Yves Chalandon, Alexandra Calmy, Alfredo Addeo	1
7	CMV Infection After Letermovir Primary Prophylaxis Discontinuation in Allogeneic Hematopoietic Cell Transplant Recipients 2023 ·Open Forum Infectious Diseases ·(unknown), Léna Royston, Stavroula Masouridi‐Levrat, Anne‐Claire Mamez, Federica Giannotti, (unknown), Christian van Delden, Yves Chalandon, Dionysios Neofytos	15
8	Allogeneic hematopoietic cell transplantation for acute myeloid leukemia with hyperdiploid complex karyotype 2023 ·Bone Marrow Transplantation ·Xavier Poiré, Myriam Labopin, Emmanuelle Polge, Arnold Ganser, Gèrard Socié, Tobias Gedde‐Dahl, Édouard Forcade, Jürgen Finke, Yves Chalandon, Claude‐Eric Bulabois, Ibrahim Yakoub‐Agha, Mahmoud Aljurf, Nicolaus Kröger, Igor Wolfgang Blau, Arnon Nagler, Jordi Esteve, Mohamad Mohty	1
9	Pharmacokinetic Modeling and Simulation with Pharmacogenetic Insights Support the Relevance of Therapeutic Drug Monitoring for Myeloablative Busulfan Dosing in Adult HSCT 2023 ·Transplantation and Cellular Therapy ·(unknown), (unknown), Sonia Khier, Youssef Daali, Michael Medinger, Joerg Halter, Dominik Heim, Yves Chalandon, Urs Schanz, Gayathri Nair, Nathan Cantoni, Jakob Passweg, Chakradhara Rao S. Uppugunduri, Marc Ansari	4
10	Bronchiolitis obliterans syndrome following SARS-CoV-2 infection in an allogeneic hematopoietic stem cell recipient 2023 ·American Journal of Transplantation ·Louise Bondeelle, Federica Giannotti, Yves Chalandon, Jérôme Le Goff, Caroline Tapparel, Anne Bergeron	1
11	Effect of pharmacokinetics and pharmacogenomics in adults with allogeneic hematopoietic cell transplantation conditioned with Busulfan 2023 ·Bone Marrow Transplantation ·(unknown), Chakradhara Rao S. Uppugunduri, Michael Medinger, (unknown), Joerg Halter, Dominik Heim, Yves Chalandon, Urs Schanz, Gayathri Nair, Nathan Cantoni, Jakob Passweg, Marc Ansari	5
12	Analysis of biological models to predict clinical outcomes based on HLA-DPB1 disparities in unrelated transplantation 2021 ·Blood Advances ·Stéphane Bühler, Helen Baldomero, Sylvie Ferrari‐Lacraz, Anne‐Claire Mamez, Stavroula Masouridi‐Levrat, Dominik Heim, Jörg Halter, Gayathri Nair, Yves Chalandon, Urs Schanz, Tayfun Güngör, Grazia Nicoloso, Jakob Passweg, Jean Villard, (unknown)	8
13	Optimal Treatment Duration of Pseudomonas aeruginosa Infections in Allogeneic Hematopoietic Cell Transplant Recipients 2020 ·Open Forum Infectious Diseases ·Flaminia Olearo, Ilona Kronig, Stavroula Masouridi‐Levrat, Yves Chalandon, Nina Khanna, Jakob Passweg, Michael Medinger, Nicolas J. Mueller, Urs Schanz, Christian van Delden, Dionysios Neofytos	10
14	Microbiologically documented infections after adult allogeneic hematopoietic cell transplantation: A 5‐year analysis within the Swiss Transplant Cohort study 2020 ·Transplant Infectious Disease ·Diem‐Lan Vu, (unknown), Stavroula Masouridi‐Levrat, Christophe Combescure, (unknown), Nina Khanna, Nicolas J. Mueller, Martina Kleber, Michael Medinger, Joerg Halter, Jakob Passweg, Antonia Müller, Urs Schanz, Yves Chalandon, Dionysios Neofytos, Christian van Delden, Laurent Kaiser, (unknown)	12
15	Epigenetic Silencing Affects l -Asparaginase Sensitivity and Predicts Outcome in T-ALL 2019 ·Clinical Cancer Research ·Aurore Touzart, Étienne Lengliné, (unknown), Mohamed Belhocine, (unknown), Xavier Thomas, Salvatore Spicuglia, Denis Puthier, Françoise Pflumio, Thibaut Leguay, Carlos Graux, Yves Chalandon, Françoise Huguet, Stéphane Leprêtre, Norbert Ifrah, Hervé Dombret, Elizabeth Macintyre, Mathilde Hunault, Nicolas Boissel, Vahid Asnafi	28
16	Clinical and biological features of PTPN2-deleted adult and pediatric T-cell acute lymphoblastic leukemia 2019 ·Blood Advances ·Marion Alcantara, Mathieu Simonin, Ludovic Lhermitte, Aurore Touzart, Marie-Émilie Dourthe, (unknown), Nathalie Grardel, Jean Michel Cayuela, Yves Chalandon, Carlos Graux, Hervé Dombret, Norbert Ifrah, Arnaud Petit, Elizabeth Macintyre, André Baruchel, Nicolas Boissel, Vahid Asnafi	14
17	Incidence and outcome of invasive fungal diseases after allogeneic hematopoietic stem cell transplantation: A Swiss transplant cohort study 2018 ·Transplant Infectious Disease ·(unknown), Susanne Stampf, B. Gerber, (unknown), Maja Weisser, Sabine Gerull, Michael Medinger, Jakob Passweg, Urs Schanz, Christian Garzoni, Christoph Berger, Yves Chalandon, Nicolas J. Mueller, Christian van Delden, Dionysios Neofytos, Nina Khanna, (unknown)	39
18	Adaptation des doses de médicament des conditionnements de greffe de cellules souches hématopoïétiques dans des populations avec comorbidité : obésité, maladie rénale chronique ou hépatopathie : recommandations de la Société francophone de greffe de moelle et de thérapie cellulaire (SFGM-TC) 2017 ·Bulletin du Cancer ·Nicolas Simon, Valérie Coiteux, Bénédicte Bruno, Sophie Taque, A Charbonnier, Laëtitia Souchet, Laure Vincent, Ibrahim Yakoub‐Agha, Yves Chalandon	6
19	Long-term follow up after allogeneic stem cell transplantation in patients with severe aplastic anemia after cyclophosphamide plus antithymocyte globulin conditioning 2011 ·Haematologica ·Johanna Konopacki, Raphaël Porcher, Marie Robin, Sabine Bieri, Jean-Michel Cayuela, (unknown), Aliénor Xhaard, A. Andréoli, Nathalie Dhédin, Anna D. Petropoulou, Paula Rodríguez‐Otero, Patricia Ribaud, Hélène Moins‐Teisserenc, (unknown), Antoine Toubert, Yves Chalandon, Gèrard Socié, Régis Peffault de Latour	28
20	Combined radioimmunotherapy and chemotherapy of human colon carcinoma grafted in nude mice, advantages and limitations. 1992 ·PubMed ·Yves Chalandon, J P Mach, André Pèlegrin, Silvio Folli, F. Buchegger	12

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact